reviewTop 10% cited
Ferucarbotran (Resovist): a new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver: properties, clinical development, and applications
European Radiology · 2003 · Vol. 13(6) · pp. 1266–1276
Peter Reimer✉(Städtisches Klinikum Karlsruhe)Thomas Balzer
Hepatocellular Carcinoma Treatment and PrognosisLiver Disease Diagnosis and TreatmentLiver Disease and TransplantationMedicineLesionInterventional radiologyRadiologyNeuroradiologyContrast (vision)Magnetic resonance imagingNuclear medicinePathologyNeurology
MeSH terms
Contrast MediaDextransHumansIronLiverLiver DiseasesLiver NeoplasmsMagnetic Resonance ImagingOxidesSafetyTime FactorsMulticenter Studies as TopicRandomized Controlled Trials as TopicClinical Trials, Phase I as TopicClinical Trials, Phase II as Topic
Citations
612
FWCI
8.07
field-weighted impact
References
43
Percentile
98%
vs. same field & year
Citations per year
Cited by
Magnetic nanoparticle design for medical diagnosis and therapy
Journal of Materials Chemistry · 2004 · 1,726 citations
Iron oxide nanoparticles: Diagnostic, therapeutic and theranostic applications
Advanced Drug Delivery Reviews · 2019 · 1,107 citations
Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications
European Radiology · 2004 · 284 citations
Toxicology of engineered nanomaterials: Focus on biocompatibility, biodistribution and biodegradation
Biochimica et Biophysica Acta (BBA) - General Subjects · 2010 · 516 citations
References
Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging
European Radiology · 2001 · 1,375 citations
Superparamagnetic iron oxide: pharmacokinetics and toxicity
American Journal of Roentgenology · 1989 · 1,038 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.